SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending as investors digest record financial results, highlighted by a significant year-over-year revenue surge and an accelerated path toward profitability that has energized long-term shareholders. Community discussion is currently dominated by debates over the company's valuation, the impact of historical share dilution, and the potential for a short squeeze as institutional interest grows alongside the expanding backlog of defense and drone infrastructure contracts.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is attracting significant attention as investors weigh recent revenue misses and satellite deployment delays against a record-high short interest and major endorsements from institutional players like BlackRock. The community remains deeply polarized, with bulls pointing to upcoming mid-June satellite launches and long-term partnerships with major carriers as primary catalysts, while bears focus on execution risks and the gap between current valuation and realized revenue.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is rallying as investors pile into the space sector ahead of upcoming Q1 earnings and anticipation surrounding the major NASA LTV contract award. The community is buzzing over the company's recent strategic acquisitions and revenue growth, with many holders focused on the potential for a technical squeeze driven by institutional interest.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest the company's recent Q1 earnings results and updated full-year guidance, while also closely monitoring progress on the commercial rollout of DefenCath and anticipation for clinical data on Rezzayo. Community discussion is focused on the impact of management's profitability turnaround, the effectiveness of ongoing share buyback efforts, and the potential for long-term growth as the company navigates reimbursement dynamics.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is attracting significant community attention as investors weigh its ongoing growth and strategic partnerships with major tech platforms against a backdrop of high short interest. Market participants are closely watching the upcoming antitrust verdict involving its PriceRunner subsidiary, which many believe could serve as a major catalyst for the stock.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors rally ahead of a high-profile plenary session at the AUA Annual Meeting, where the company will present extended clinical data for its lead prostate cancer asset. The community is actively discussing the potential for a significant rerating or buyout, while heightened short interest and strong volume drive speculation regarding a possible short squeeze.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance Corp. ($PSKY) is currently a major focal point as investors closely watch the Warner Bros. Discovery ($WBD) merger process, with the community actively debating the company's valuation, potential shareholder dilution, and the long-term impact of its debt load. Investors are expressing significant frustration over recent price volatility and perceived lack of transparency, while balancing skepticism toward executive compensation against high hopes for the company's future as an AI-integrated media powerhouse.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following a strategic supply agreement with Lumilens, which includes an initial order and a long-term commercial roadmap valued at over $500 million. Investors are actively discussing the company's ability to scale manufacturing for AI data center infrastructure, while the stock experiences high volatility and intense community debate surrounding warrant dilution and the transition from pre-revenue status to commercial production.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is currently rallying as investors digest the launch of daily dividends on its SATA preferred stock alongside a robust increase in Bitcoin treasury holdings. The community is actively discussing the company's debt-free status and the potential for these daily yields to drive institutional interest, fueling bullish speculation about the stock's future performance.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining momentum as investors anticipate the final data from the Phase 3 REGAL trial, with the community actively speculating on a potential short squeeze fueled by significant institutional buying and high trading volume. Discussions are focused on the company's oncology pipeline, with bulls viewing upcoming investor presentations and the imminent trial milestone as key catalysts for a significant valuation rerating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for...

Promising Penny Stocks To Watch Today - May 3rd

Esperion Therapeutics, SOBR Safe, JetBlue Airways, BigBear.ai, Lakewood-Amedex Biotherapeutics, Beyond Meat, and Direxion Daily AMD Bear 1X Shares are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small public companiesc...

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive...

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PR Newswire SARASOTA, Fla...

<ul class="summary-bullets"><li>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.</li><li>This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers.</li><li>Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.</li></ul>Shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) soared more than 70% in Friday’s pre-market trade, a day after the company announced a direct listing on the Nasdaq stock exchange.Lakewood-Amedex Biotherapeutics began trading on the Nasdaq on Thursday, closing the day up over 8% and with a market capitalization of $122 million.<a href="https://stocktwits.com/symbol/LABT">Lakewood-Amedex Biotherapeutics shares</a> were up nearly 50% in Friday’s pre-market trade.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory, with message volumes at ‘extremely high’ levels. LABT was among the top-trending tickers on the platform at the time of writing.One user stated that the real test for LABT would be how it handles the $14 level on any pullback today would be the real test for the stock.<stembedurl>https://stocktwits.com/Olivia_Strickland/message/651253709</stembedurl><h2 class="st-heading-2">Chairman Says Listing Will Accelerate Development</h2>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers (iDFU).Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.Cooper added that of the 40 million diabetes patients in the U.S., around one-third develop DFU in their lifetime. He stated that the DFU will become infected in around half of these patients.“Numerous patients experience more than one of these events in their life, and antibiotic-resistant bacterial strains are a major concern for the treatment of these patients. We look forward to accelerating our work targeting this major unmet need,” Cooper added.<h2 class="st-heading-2">Early Exploratory Trials Showed No Safety Concerns, Says Company</h2>The company stated that early exploratory trials of Nu-3 at subclinical doses showed no safety concerns, while indicating a trend toward antimicrobial activity and improved wound healing.Based on these findings, the company plans to initiate a Phase 2a study to assess safety and dose response, followed by a placebo-controlled Phase 2b trial comparing different doses.The program will also evaluate the optimal administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers, the company said.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Lakewood-Amedex Biotherapeutics started trading on the Nasdaq on Thursday, closing the day with gains of over 8% and a market capitalization of $122 million.

LABT Stock Soars 50% After Nasdaq Debut – Retail Says $14 Is The Line In The Sand

Equity

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol 'LABT' Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the...

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Lakewood-Amedex Biotherapeutics Inc.

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it 

Cerebras ($CRBS) IPO day is Thursday, how are you playing it?  
 
Drop a comment with your strategy.

LABT
Lakewood-Amedex Biotherapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest LABT News

LABTLakewood-Amedex Biotherapeutics Inc.